Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Targeting ferroptosis pathways to overcome immunotherapy resistance in non-melanoma skin cancers. Local targets link to admitted publications; unresolved targets remain external evidence.
Non-melanoma skin cancers: Biological and clinical features
10.3390/ijms21155394 · 2020 · External reference
Overview of skin cancer types and prevalence rates across continents
10.1016/j.cpt.2024.08.002 · 2025 · External reference
Cutaneous squamous cell carcinoma in immunocompromised patients
10.3390/cancers17213476 · 2025 · External reference
Merkel cell carcinoma in solid organ transplant recipients: Prognosis and response to immunotherapy
10.1093/bjd/ljaf304 · 2025 · External reference
Immune checkpoint inhibitors in Merkel cell carcinoma of the skin: A 2025 comprehensive review
10.3390/cancers17193272 · 2025 · External reference
Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies
10.1038/s41392-024-01769-5 · 2024 · External reference
Targeting regulated cell death: Apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity
10.1515/jtim-2025-0004 · 2025 · External reference
Ferroptosis: A double-edged sword
10.1038/s41420-024-02037-9 · 2024 · External reference
Ferroptosis and the tumor microenvironment
10.1186/s13046-024-03235-0 · 2024 · External reference
Immunometabolism of ferroptosis in the tumor microenvironment
10.3389/fonc.2024.1441338 · 2024 · External reference
Research progress on the cross-regulation between ferroptosis and immunogenic cell death in tumor micro-environment
10.2307/jj.30347516.17 · 2025 · External reference
In defence of ferroptosis
10.1038/s41392-024-02088-5 · 2025 · External reference
Leveraging tissue engineering for skin cancer models
10.1007/5584_2022_755 · 2023 · External reference
Metabolism-based scoring of cutaneous squamous cell carcinoma to predict tumour features and responses to treatment with dihydroorotate dehydrogenase inhibitors
10.1093/bjd/ljaf253 · 2025 · External reference
Immune checkpoints and cellular landscape of the tumor microenvironment in non-melanoma skin cancer (NMSC)
10.3390/cells13191615 · 2024 · External reference
Unraveling the landscape of non-melanoma skin cancer through single-cell RNA sequencing technology
10.3389/fonc.2024.1500300 · 2024 · External reference
Ferroptosis meets cancer immunotherapy: Overcoming the crosstalk challenges through advanced drug delivery strategies
10.1016/j.apsb.2025.09.043 · 2025 · External reference
Ferroptosis induction by engineered liposomes for enhanced tumor therapy
10.3762/bjnano.16.97 · 2025 · External reference
Synchronously delivering melittin and evoking ferroptosis via tumor microenvironment-triggered self-destructive metal-organic frameworks to boost cancer immunotherapy
10.1002/adhm.202500003 · 2025 · External reference
High carbonyl graphene oxide suppresses colorectal cancer cell proliferation and migration by inducing ferroptosis via the system Xc-/GSH/GPX4 axis
10.3390/pharmaceutics16121605 · 2024 · External reference
Graphene oxide nanosheets toxicity in mice is dependent on protein corona composition and host immunity
10.1021/acsnano.4c08561 · 2024 · External reference
Recent advances and future prospective of topical and transdermal delivery systems
10.3389/fddev.2022.957732 · 2022 · External reference
Nanodelivery systems for topical management of skin disorders
10.1021/acs.molpharmaceut.0c00154 · 2021 · External reference
A multifunctional Fe-EGCG@RSL3 nanomedicine synergizes ferroptosis induction and tumor microenvironment remodeling for enhanced bladder cancer immunotherapy
10.34133/research.0735 · 2025 · External reference
Boosting cancer immunotherapy: Drug delivery systems leveraging ferroptosis and immune checkpoint blockade
10.3788/aos241654 · 2025 · External reference
Advancements in Nano-delivery systems for photodynamic and photothermal therapy to induce immunogenic cell death in tumor immunotherapy
10.2147/ijn.s514659 · 2025 · External reference
Nanocarriers in skin cancer treatment: Emerging drug delivery approaches and innovations
10.1016/j.ntm.2024.100068 · 2025 · External reference
Recent global patterns in skin cancer incidence, mortality, and prevalence
10.1097/cm9.0000000000003416 · 2025 · External reference
Epidemiology of keratinocyte skin cancer with a focus on cutaneous squamous cell carcinoma
10.3390/cancers16030606 · 2024 · External reference
Global burden of non-melanoma skin cancers among older adults: A comprehensive analysis using machine learning approaches
10.1038/s41598-025-99605-5 · 2025 · External reference
The management of malignant skin cancers
10.1016/j.mpsur.2017.06.013 · 2017 · External reference
The state of the art in the treatment of actinic keratosis and field cancerization: A narrative review
10.3390/jpm15090421 · 2025 · External reference
Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin
10.1186/s12885-017-3663-0 · 2017 · External reference
COL10A1 expression distinguishes a subset of cancer-associated fibroblasts present in the stroma of high-risk basal cell carcinoma
10.1093/bjd/ljae258 · 2024 · External reference
GREM1 is expressed in the cancer-associated myofibroblasts of basal cell carcinomas
10.1371/journal.pone.0174565 · 2017 · External reference
Advanced cutaneous squamous cell carcinoma: Biology, immunotherapy, and evolving prognostic factors
10.3390/biomedicines13123010 · 2025 · External reference
S2k guideline basal cell carcinoma of the skin (update 2023)
10.1111/ddg.15566 · 2024 · External reference
High-dimensional and spatial analysis reveals immune landscape-dependent progression in cutaneous squamous cell carcinoma
10.1158/1078-0432.ccr-22-1332 · 2022 · External reference
The tumor stroma of squamous cell carcinoma: A complex environment that fuels cancer progression
10.3390/cancers16091727 · 2024 · External reference
Tumor-associated neutrophils dampen adaptive immunity and promote cutaneous squamous cell carcinoma development
10.3390/cancers12071860 · 2020 · External reference
Merkel cell carcinoma: An updated review focused on bone and bone marrow metastases
10.3390/cancers17132253 · 2025 · External reference
Japanese dermatological association guidelines: Clinical questions of guidelines for Merkel cell carcinoma 2025
10.1111/1346-8138.17974 · 2025 · External reference
Risk factors and innovations in risk assessment for melanoma, basal cell carcinoma, and squamous cell carcinoma
10.3390/cancers16051016 · 2024 · External reference
Ultraviolet (UV) radiation: A double-edged sword in cancer development and therapy
10.1186/s43556-024-00209-8 · 2024 · External reference
Marjolin ulcer: A rare clinical entity that every health professional should be informed about: A narrative review
10.1007/s12672-025-02948-8 · 2025 · External reference
Arsenic exposure and risk of skin cancer (melanoma and non-melanoma): A systematic review and meta-analysis
10.1016/j.abd.2025.501161 · 2025 · External reference
Tobacco smoking is associated with cutaneous squamous cell carcinoma but not with basal cell carcinoma or melanoma in adult subjects at risk of skin cancer: A cross-sectional study
10.18332/tid/185299 · 2024 · External reference
Molecular targeted therapies for cutaneous squamous cell carcinoma: Recent developments and clinical implications
10.17179/excli2023-6489 · 2024 · External reference
Current insights and future perspectives of ultraviolet radiation (UV) exposure: Friends and foes to the skin and beyond the skin
10.1016/j.envint.2024.108535 · 2024 · External reference
Basal cell carcinoma and hedgehog pathway inhibitors: Focus on immune response
10.3389/fmed.2022.893063 · 2022 · External reference
Beyond antioxidants: How redox pathways shape cellular signaling and disease outcomes
10.3390/antiox14091142 · 2025 · External reference
Merkel-cell carcinoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up
10.1016/j.esmoop.2024.102977 · 2024 · External reference
Merkel cell polyomavirus: Infection, genome, transcripts and its role in development of Merkel cell carcinoma
10.3390/cancers15020444 · 2023 · External reference
Kit-mediated autophagy suppression driven by a viral oncoprotein emerges as a crucial survival mechanism in Merkel cell carcinoma
10.1080/15548627.2025.2477385 · 2025 · External reference
Understanding Merkel cell carcinoma: Pathogenic signaling, extracellular matrix dynamics, and novel treatment approaches
10.3390/cancers17071212 · 2025 · External reference
Immunometabolism of regulatory T cells in cancer
10.1038/s41388-025-03458-1 · 2025 · External reference
Tumor-infiltrating T cells in skin basal cell carcinomas and squamous cell carcinomas: Global Th1 preponderance with Th17 enrichment-A cross-sectional study
10.3390/cells13110964 · 2024 · External reference
Regulatory T cells in cancer: From immunosuppression to therapeutic targeting
10.3389/fimmu.2025.1703211 · 2025 · External reference
Enhancing immunotherapy response in melanoma: Myeloid-derived suppressor cells as a therapeutic target
10.1172/jci170762 · 2023 · External reference
Targeted modulation of myeloid-derived suppressor cells in the tumor microenvironment: Implications for cancer therapy
10.1016/j.biopha.2024.117590 · 2024 · External reference
Tumor-associated macrophages: An effective player of the tumor microenvironment
10.3389/fimmu.2023.1295257 · 2023 · External reference
Targeting of TAMs: Can we be more clever than cancer cells
10.1038/s41423-024-01232-z · 2024 · External reference
The tumor immune microenvironment: Implications for cancer immunotherapy, treatment strategies, and monitoring approaches
10.3389/fimmu.2025.1621812 · 2025 · External reference
Lactate at the crossroads of tumor metabolism and immune escape: A new frontier in cancer therapy
10.1186/s12967-025-07272-x · 2025 · External reference
Impact of lactate on immune cell function in the tumor microenvironment: Mechanisms and therapeutic perspectives
10.3389/fimmu.2025.1563303 · 2025 · External reference
Immune checkpoint inhibition in non-melanoma skin cancer: A review of current evidence
10.3389/fonc.2021.734354 · 2021 · External reference
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
10.1136/jitc-2023-008325 · 2024 · External reference
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial
10.1016/s1470-2045(19)30728-4 · 2020 · External reference
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: An open-label, multi-centre, single-arm, phase 2 trial
10.1016/s1470-2045(21)00126-1 · 2021 · External reference
Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches
10.1038/s41392-025-02280-1 · 2025 · External reference
PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy
10.1016/j.cellin.2024.100146 · 2024 · External reference
Combination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer-a brief update
10.3389/fimmu.2025.1680838 · 2025 · External reference
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
10.1016/j.immuni.2024.01.010 · 2024 · External reference
TIM-3 teams up with PD-1 in cancer immunotherapy: Mechanisms and perspectives
10.1186/s43556-025-00267-6 · 2025 · External reference
Enhancer of zeste homolog 2 inhibition induces HLA class I re-expression in Merkel cell carcinoma
10.1016/j.jid.2023.10.036 · 2024 · External reference
An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma
10.1016/j.ejca.2024.115121 · 2025 · External reference
PD-1 and beyond to activate T cells in cutaneous squamous cell cancers: The case for 4-1BB and VISTA antibodies in combination therapy
10.3390/cancers13133310 · 2021 · External reference
Mechanisms of immunotherapy in cutaneous squamous cell carcinoma in the tumor microenvironment
10.3389/fimmu.2025.1660272 · 2025 · External reference
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
10.3389/fimmu.2022.1061394 · 2022 · External reference
The emerging roles of Hedgehog signaling in tumor immune microenvironment
10.3389/fonc.2023.1171418 · 2023 · External reference
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: Mechanistic insights from detailed biomarker analyses
10.1136/jitc-2024-009803 · 2024 · External reference
Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma
10.1038/s41467-024-49718-8 · 2024 · External reference
Nanoparticles presenting potent TLR7/8 agonists enhance anti-PD-L1 immunotherapy in cancer treatment
10.1021/acs.biomac.0c00812 · 2020 · External reference
Chemotherapy-induced neoantigen nanovaccines enhance checkpoint blockade cancer immunotherapy
10.1021/acsnano.3c03274 · 2023 · External reference
Metabolic reprogramming and immune evasion: The interplay in the tumor microenvironment
10.1186/s40364-024-00646-1 · 2024 · External reference
Metabolic gatekeepers: Harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment
10.1038/s41419-024-07122-6 · 2024 · External reference
The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer
10.1080/25785826.2025.2550795 · 2025 · External reference
Lactate and lactylation in cancer
10.1038/s41392-024-02082-x · 2025 · External reference
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
10.1016/j.ccell.2022.01.001 · 2022 · External reference
Regulation of CD8+ T cells by lipid metabolism in cancer progression
10.1038/s41423-024-01224-z · 2024 · External reference
The impact of aberrant lipid metabolism on the immune microenvironment of gastric cancer: A mini review
10.3389/fimmu.2025.1639823 · 2025 · External reference
Targeting glutamine metabolism as a potential target for cancer treatment
10.1186/s13046-025-03430-7 · 2025 · External reference
Cystine transporter SLC7A11/xCT in cancer: Ferroptosis, nutrient dependency, and cancer therapy
10.1007/s13238-020-00789-5 · 2021 · External reference
NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8
10.1126/sciadv.ade9585 · 2023 · External reference
ATM orchestrates ferritinophagy and ferroptosis by phosphorylating NCOA4
10.1080/15548627.2023.2170960 · 2023 · External reference
MYCN mediates TFRC-dependent ferroptosis and reveals vulnerabilities in neuroblastoma
10.1038/s41419-021-03790-w · 2021 · External reference
Iron homeostasis and ferroptosis in human diseases: Mechanisms and therapeutic prospects
10.1038/s41392-024-01969-z · 2024 · External reference
The interaction between ferroptosis and inflammatory signaling pathways
10.1038/s41419-023-05716-0 · 2023 · External reference
A guideline on the molecular ecosystem regulating ferroptosis
10.1038/s41556-024-01360-8 · 2024 · External reference
Copper-dependent autophagic degradation of GPX4 drives ferroptosis
10.1080/15548627.2023.2165323 · 2023 · External reference
Palmitoylation-dependent regulation of GPX4 suppresses ferroptosis
10.1038/s41467-025-56344-5 · 2025 · External reference
FSP1 confers ferroptosis resistance in KEAP1 mutant non-small cell lung carcinoma in NRF2-dependent and -independent manner
10.1038/s41419-023-06070-x · 2023 · External reference
Ferroptosis-related local immune cytolytic activity in tumor microenvironment of basal cell and squamous cell carcinoma
10.18632/aging.204057 · 2022 · External reference
Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease
10.1016/j.cell.2017.09.021 · 2017 · External reference
MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells
10.1038/s41419-020-02939-3 · 2020 · External reference
Targeting ferroptosis opens new avenues for the development of novel therapeutics
10.1038/s41392-023-01606-1 · 2023 · External reference
Implantation of hydrogel-liposome nanoplatform inhibits glioblastoma relapse by inducing ferroptosis
10.1016/j.ajps.2023.100800 · 2023 · External reference
Regulation of ferroptotic cancer cell death by GPX4
10.1016/j.cell.2013.12.010 · 2014 · External reference
RSL3-loaded nanoparticles amplify the therapeutic potential of cold atmospheric plasma
10.1186/s12951-025-03211-6 · 2025 · External reference
Utilization of DOX-Fe complex and RSL3 co-loaded liposomes in ferroptosis-enhanced treatment of triple-negative breast cancer
10.1080/10717544.2025.2592412 · 2025 · External reference
Molecular mechanisms of ferroptosis and their involvement in brain diseases
10.1016/j.pharmthera.2023.108373 · 2023 · External reference
Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity
10.1038/s41467-022-31218-2 · 2022 · External reference
Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer
10.1126/scitranslmed.adg3049 · 2023 · External reference
The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions
10.1016/j.ccell.2024.03.011 · 2024 · External reference
Ferroptosis: Mechanism and connections with cutaneous diseases
10.3389/fcell.2022.1079548 · 2023 · External reference
Ferroptosis: Mechanisms and links with diseases
10.1038/s41392-020-00428-9 · 2021 · External reference
System XC-/GSH/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy
10.3389/fphar.2022.910292 · 2022 · External reference
FSP1 is a glutathione-independent ferroptosis suppressor
10.1038/s41586-019-1707-0 · 2019 · External reference
Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression
10.1038/s41467-023-40822-9 · 2023 · External reference
Lipidomics revealed alterations in glycerophospholipid metabolism in skin squamous cell carcinoma
10.3389/fmolb.2024.1356043 · 2024 · External reference
Virus-positive Merkel cell carcinoma is an independent prognostic group with distinct predictive biomarkers
10.1158/1078-0432.ccr-20-0864 · 2021 · External reference
Artesunate affects T antigen expression and survival of virus-positive Merkel cell carcinoma
10.3390/cancers12040919 · 2020 · External reference
Signaling pathways and therapeutic strategies in advanced basal cell carcinoma
10.3390/cells12212534 · 2023 · External reference
Synthetic lethal CRISPR screen identifies a cancer cell-intrinsic role of PD-L1 in regulation of vulnerability to ferroptosis
10.1016/j.celrep.2024.114477 · 2024 · External reference
Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling
10.1126/sciadv.adi2012 · 2024 · External reference
CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
10.1038/s41586-019-1170-y · 2019 · External reference
Tumour cell-expressed PD-L1 reprograms lipid metabolism via EGFR/ITGB4/SREBP1c signalling in liver cancer
10.1016/j.jhepr.2024.101009 · 2024 · External reference
Therapeutic induction of ferroptosis in tumors using PD-L1 targeting antibody nanogel conjugates
10.1016/j.chembiol.2024.10.014 · 2024 · External reference
Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization
10.1016/j.ymthe.2021.03.013 · 2021 · External reference
Revisiting of cancer immunotherapy: Insight from the dialogue between glycolysis and PD-1/PD-L1 axis in the tumor microenvironment
10.7150/ijbs.104079 · 2025 · External reference
Towards immunotherapy-induced normalization of the tumor microenvironment
10.3389/fcell.2022.908389 · 2022 · External reference
Modulating ferroptosis sensitivity: Environmental and cellular targets within the tumor microenvironment
10.1186/s13046-023-02925-5 · 2024 · External reference
Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer
10.1038/s41418-022-01008-w · 2022 · External reference
Targeting Wnt/β-catenin signaling exacerbates ferroptosis and increases the efficacy of melanoma immunotherapy via the regulation of MITF
10.3390/cells11223580 · 2022 · External reference
Characterization of ferroptosis in kidney tubular cell death under diabetic conditions
10.1038/s41419-021-03452-x · 2021 · External reference
UBR5 mediates colorectal cancer chemoresistance by attenuating ferroptosis via Lys 11 ubiquitin-dependent stabilization of Smad3-SLC7A11 signaling
10.1016/j.redox.2024.103349 · 2024 · External reference
Cancer-associated fibroblasts reprogram cysteine metabolism to increase tumor resistance to ferroptosis in pancreatic cancer
10.7150/thno.89805 · 2024 · External reference
Ferroptosis in cancer: Epigenetic control and therapeutic opportunities
10.3390/biom14111443 · 2024 · External reference
Acute lymphoblastic leukemia necessitates GSH-dependent ferroptosis defenses to overcome FSP1-epigenetic silencing
10.1016/j.redox.2022.102408 · 2022 · External reference
Low-dose hypomethylating agents cooperate with ferroptosis inducers to enhance ferroptosis by regulating the DNA methylation-mediated MAGEA6-AMPK-SLC7A11-GPX4 signaling pathway in acute myeloid leukemia
10.1186/s40164-024-00489-4 · 2024 · External reference
HDAC inhibitors activate lipid peroxidation and ferroptosis in gastric cancer
10.1016/j.bcp.2024.116257 · 2024 · External reference
HDAC inhibition induces EMT and alterations in cellular iron homeostasis to augment ferroptosis sensitivity in SW13 cells
10.1016/j.redox.2021.102149 · 2021 · External reference
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma
10.21037/tlcr-21-303 · 2021 · External reference
A dual PI3K/HDAC inhibitor induces immunogenic ferroptosis to potentiate cancer immune checkpoint therapy
10.1158/0008-5472.can-21-1547 · 2021 · External reference
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
10.1172/jci138560 · 2021 · External reference
A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response
10.1126/sciimmunol.abg7836 · 2021 · External reference
Stem-like T cells and niches: Implications in human health and disease
10.3389/fimmu.2022.907172 · 2022 · External reference
Immunometabolism of CD8+ T cell differentiation in cancer
10.1016/j.trecan.2024.03.010 · 2024 · External reference
CD8+ T cells sustain antitumor response by mediating crosstalk between adenosine A2A receptor and glutathione/GPX4
10.1172/jci170071 · 2024 · External reference
Cystine deprivation triggers CD36-mediated ferroptosis and dysfunction of tumor infiltrating CD8+ T cells
10.1038/s41419-024-06503-1 · 2024 · External reference
Potential mechanisms of cancer stem-like progenitor T-cell bio-behaviours
10.1002/ctm2.1817 · 2024 · External reference
LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity
10.1016/j.cell.2024.07.016 · 2024 · External reference
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors
10.1016/j.immuni.2021.05.003 · 2021 · External reference
Ferroptosis nanomedicine: Clinical challenges and opportunities for modulating tumor metabolic and immunological landscape
10.1021/acsnano.3c04632 · 2023 · External reference
Biocompatible polymer-modified nanoplatform for ferroptosis-enhanced combination cancer therapy
10.1002/mabi.202300215 · 2023 · External reference
Tumor microenvironment triggered iron-based metal organic frameworks for magnetic resonance imaging and photodynamic-enhanced ferroptosis therapy
10.1016/j.jcis.2025.01.119 · 2025 · External reference
Mitigating metal-organic framework (MOF) toxicity for biomedical applications
10.1016/j.cej.2023.144400 · 2023 · External reference
Safety of metal-organic framework nanoparticles for biomedical applications: An in vitro toxicity assessment
10.1016/j.inoche.2023.110655 · 2023 · External reference
Quercetin-loaded Ti3C2Tx MXene nanosheets enhance chemo-photothermal therapy in gastric cancer
10.1016/j.matdes.2025.114392 · 2025 · External reference
Polydopamine(PDA)-coated diselenide-bridged mesoporous silica-based nanoplatform for neuroprotection by reducing oxidative stress and targeting neuroinflammation in intracerebral hemorrhage
10.1186/s12951-024-03023-0 · 2024 · External reference
Mechanistic investigation into the selective anticancer cytotoxicity and immune system response of surface-functionalized, dichloroacetate-loaded, UiO-66 nanoparticles
10.1021/acsami.7b17756 · 2018 · External reference
Recent advances in surface decoration of nanoparticles in drug delivery
10.3389/fnano.2024.1456939 · 2024 · External reference
Localized topical drug delivery systems for skin cancer: Current approaches and future prospects
10.3389/fnano.2022.1006628 · 2022 · External reference
Activation of lysosomal iron triggers ferroptosis in cancer
10.1038/s41586-025-08974-4 · 2025 · External reference
Nanoparticles for ferroptosis therapy in cancer
10.3390/pharmaceutics13111785 · 2021 · External reference
Advances in ferroptosis-inducing agents by targeted delivery system in cancer therapy
10.2147/ijn.s448715 · 2024 · External reference
Highly selective and effective ferroptosis liposomal nanodrugs for synergistic antitumor therapy
10.1016/j.cej.2024.152480 · 2024 · External reference
Metabolic nanoregulators induce ferroptosis and change metabolite flow to reverse immunosuppressive tumor microenvironment
10.1021/acsnano.4c13425 · 2024 · External reference
Metal-polyphenol-network coated Prussian blue nanoparticles for synergistic ferroptosis and apoptosis via triggered GPX4 inhibition and concurrent in situ bleomycin toxification
10.1002/smll.202103919 · 2021 · External reference
Iron-based nanovehicle delivering Fin56 for hyperthermia-boosted ferroptosis therapy against osteosarcoma
10.2147/ijn.s441112 · 2024 · External reference
Exosome-based delivery strategies for tumor therapy: An update on modification, loading, and clinical application
10.1186/s12951-024-02298-7 · 2024 · External reference
Cell membrane-coated nanoparticles: A new frontier in immunomodulation
10.1002/anbr.202400012 · 2024 · External reference
Exosomes: A review of biologic function, diagnostic and targeted therapy applications, and clinical trials
10.1186/s12929-024-01055-0 · 2024 · External reference
Exosomes and ferroptosis: Roles in tumour regulation and new cancer therapies
10.7717/peerj.13238 · 2022 · External reference
The crosstalk between exosomes and ferroptosis: A review
10.1038/s41420-024-01938-z · 2024 · External reference
Targeting drugs to tumours using cell membrane-coated nanoparticles
10.1038/s41571-022-00699-x · 2023 · External reference
Enhanced cancer immunotherapy through synergistic ferroptosis and immune checkpoint blockade using cell membrane-coated nanoparticles
10.1186/s12645-023-00234-2 · 2023 · External reference
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
10.1016/j.semcancer.2019.07.017 · 2020 · External reference
Cold and hot tumors: From molecular mechanisms to targeted therapy
10.1038/s41392-024-01979-x · 2024 · External reference
Molecular repolarisation of tumour-associated macrophages
10.3390/molecules24010009 · 2019 · External reference
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
10.1186/s13045-024-01535-8 · 2024 · External reference
Cell membrane coated nanoparticles as a biomimetic drug delivery platform for enhancing cancer immunotherapy
10.1039/d4nr00284a · 2024 · External reference
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
10.1016/j.ccell.2023.02.014 · 2023 · External reference
Encapsulated checkpoint blocker before chemotherapy: The optimal sequence of anti-CTLA-4 and doxil combination therapy
10.2147/ijn.s260760 · 2020 · External reference
STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy
10.1126/sciimmunol.add1153 · 2023 · External reference
A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance
10.1016/j.biomaterials.2024.122788 · 2025 · External reference
Personalized nanovaccines for treating solid cancer metastases
10.1186/s13045-024-01628-4 · 2024 · External reference
The application of nanoparticles-based ferroptosis, pyroptosis and autophagy in cancer immunotherapy
10.1186/s12951-024-02297-8 · 2024 · External reference
Ferroptosis: CD8+ T cells' blade to destroy tumor cells or poison for self-destruction
10.1038/s41420-025-02415-x · 2025 · External reference
The release and activity of HMGB1 in ferroptosis
10.1016/j.bbrc.2019.01.090 · 2019 · External reference
10.1016/j.ccell.2022.02.003
10.1016/j.ccell.2022.02.003 · External reference
A STING-activating nanovaccine for cancer immunotherapy
10.1038/nnano.2017.52 · 2017 · External reference
Photodynamic therapy combined with ferroptosis is a synergistic antitumor therapy strategy
10.3390/cancers15205043 · 2023 · External reference
Anti-PD-L1 DNAzyme loaded photothermal Mn2+/Fe3+ hybrid metal-phenolic networks for cyclically amplified tumor ferroptosis-immunotherapy
10.1002/adhm.202102315 · 2022 · External reference
Triple-pathway cGAS-STING activation collaborated with ferroptosis-induced immunogenic cell death for boosting systemic colorectal cancer immunotherapy
10.1016/j.nantod.2024.102484 · 2024 · External reference
Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy
10.1016/j.biopha.2024.116482 · 2024 · External reference
Synergistic ferroptosis-immunotherapy nanoplatforms: Multidimensional engineering for tumor microenvironment remodeling and therapeutic optimization
10.1007/s40820-025-01862-6 · 2026 · External reference
A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers
10.1038/s41467-022-29905-1 · 2022 · External reference
CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer
10.1038/s41419-023-05803-2 · 2023 · External reference
SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation
10.1016/j.molcel.2023.10.042 · 2023 · External reference
Serum metabolite biomarkers predictive of response to PD-1 blockade therapy in non-small cell lung cancer
10.3389/fmolb.2021.678753 · 2021 · External reference
Integrated tissue proteome and metabolome reveal key elements and regulatory pathways in cutaneous squamous cell carcinoma
10.1016/j.jprot.2021.104320 · 2021 · External reference
Metabolomic profiling and accurate diagnosis of basal cell carcinoma by MALDI imaging and machine learning
10.1111/exd.15141 · 2024 · External reference
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: An observational study
10.1136/jitc-2022-004879 · 2022 · External reference
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma
10.1016/j.xcrm.2024.101663 · 2024 · External reference
Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
10.1073/pnas.1821323116 · 2019 · External reference
Context-dependent regulation of ferroptosis sensitivity
10.1016/j.chembiol.2022.06.004 · 2022 · External reference
In vivo CRISPR interference screen reveals long noncoding RNA portfolio crucial for cutaneous squamous cell carcinoma tumor growth
10.1016/j.jid.2025.04.038 · 2026 · External reference
Toxicity of metal-organic framework nanoparticles: From essential analyses to potential applications
10.1039/d1cs00918d · 2022 · External reference
Role of reactive oxygen species in the toxicity of two-dimensional nanomaterials: A study on layered Ti3C2 MXenes
10.1016/j.nantod.2023.101925 · 2023 · External reference
Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent
10.1038/s41565-023-01585-y · 2024 · External reference
Reciprocal interaction with neutrophils facilitates cutaneous accumulation of liposomes
10.1021/acsnano.4c06638 · 2024 · External reference
Poly(N-methyl-N-vinylacetamide): A strong alternative to PEG for lipid-based nanocarriers delivering siRNA
10.1002/adhm.202302712 · 2024 · External reference
Recent progress in transdermal nanocarriers and their surface modifications
10.3390/molecules26113093 · 2021 · External reference
Meta-analysis of nanoparticle distribution in tumors and major organs in tumor-bearing mice
10.1021/acsnano.3c04037 · 2023 · External reference
Physical enhancement
10.3390/nano11020335 · 2021 · External reference
Enhanced transdermal drug delivery techniques: An extensive review of patents
10.2174/187221109788452285 · 2009 · External reference
Ferroptosis in cancer and cancer immunotherapy
10.1002/cac2.12250 · 2022 · External reference
Prognostic and immunological role of key genes of ferroptosis in pan-cancer
10.3389/fcell.2021.748925 · 2021 · External reference
Long-chain polyunsaturated lipids associated with responsiveness to anti-PD-1 therapy are colocalized with immune infiltrates in the tumor microenvironment
10.1016/j.jbc.2023.102902 · 2023 · External reference
Nanoparticles as a therapeutic delivery system for skin cancer prevention and treatment
10.1016/j.xjidi.2023.100197 · 2023 · External reference
Nanomedicine-induced programmed cell death in cancer therapy: Mechanisms and perspectives
10.1038/s41420-024-02121-0 · 2024 · External reference
